RVMD

Revolution Medicines, Inc.

• TipRanks·1d ago

  Analysts Are Bullish on Top Healthcare Stocks: Compugen (CGEN), Revolution Medicines (RVMD)

• TipRanks·2d ago

  LifeSci Capital Sticks to Its Buy Rating for Revolution Medicines (RVMD)

• Simply Wall St·3d ago

  A Look At Revolution Medicines (RVMD) Valuation After Starting Pivotal Phase 3 RASolute 303 Trial

• Seeking Alpha·6d ago

  Tango a new Buy at Canaccord Genuity on 2026 catalysts

• TipRanks·6d ago

  Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Nuo Therapeutics (AURX)

• TipRanks·6d ago

  Revolution Medicines begins treating patients in RASolute 303

• Reuters·6d ago

  Revolution Medicines starts Phase 3 RASolute 303 trial of daraxonrasib in metastatic pancreatic cancer

• Reuters·6d ago

  REVOLUTION MEDICINES BEGINS TREATING PATIENTS IN PHASE 3 RASOLUTE 303 TRIAL EVALUATING DARAXONRASIB AS FIRST LINE TREATMENT FOR PATIENTS WITH METASTATIC PANCREATIC CANCER

• TipRanks·6d ago

  Revolution Medicines (RVMD) Gets a Buy from Wells Fargo

• TipRanks·04/01 11:36

  Piper Sandler Reaffirms Their Buy Rating on Revolution Medicines (RVMD)

• Simply Wall St·04/01 03:24

  Is Early RAS(ON) Pancreatic Cancer Data Altering The Investment Case For Revolution Medicines (RVMD)?

• TipRanks·03/30 16:30

  Revolution Medicines and Summit Therapeutics Advance Broad RAS(ON) Combo Study in Solid Tumors

• Simply Wall St·03/29 19:07

  A Look At Revolution Medicines (RVMD) Valuation As Cash Flows Clash With Popular Fair Value Estimates

• Reuters·03/27 00:04

  Revolution Medicines Chief Global Commercialization Officer Anthony Mancini disposes of common shares; $3,542,000 drops from sales on March 25, 2026

• Reuters·03/26 22:44

  Revolution Medicines files initial beneficial ownership statement; Chief Global Commercialization Officer Anthony Mancini reports 54,400 common shares